- Home
- INBS vs RNAZ Comparison
INBS vs RNAZ Comparison
Compare INBS & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBS
- RNAZ
- Stock Information
- Founded
- INBS 2016
- RNAZ 2016
- Country
- INBS United States
- RNAZ United States
- Employees
- INBS N/A
- RNAZ N/A
- Industry
- INBS Medical Specialities
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- INBS Health Care
- RNAZ Health Care
- Exchange
- INBS Nasdaq
- RNAZ Nasdaq
- Market Cap
- INBS 9.6M
- RNAZ 8.7M
- IPO Year
- INBS N/A
- RNAZ 2021
- Fundamental
- Price
- INBS $1.01
- RNAZ $11.17
- Analyst Decision
- INBS
- RNAZ Strong Buy
- Analyst Count
- INBS 0
- RNAZ 1
- Target Price
- INBS N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- INBS 376.2K
- RNAZ 423.8K
- Earning Date
- INBS 11-07-2025
- RNAZ 11-14-2025
- Dividend Yield
- INBS N/A
- RNAZ N/A
- EPS Growth
- INBS N/A
- RNAZ N/A
- EPS
- INBS N/A
- RNAZ N/A
- Revenue
- INBS $3,052,532.00
- RNAZ N/A
- Revenue This Year
- INBS $778.48
- RNAZ N/A
- Revenue Next Year
- INBS N/A
- RNAZ N/A
- P/E Ratio
- INBS N/A
- RNAZ N/A
- Revenue Growth
- INBS N/A
- RNAZ N/A
- 52 Week Low
- INBS $0.92
- RNAZ $6.15
- 52 Week High
- INBS $2.75
- RNAZ $528.44
- Technical
- Relative Strength Index (RSI)
- INBS 41.15
- RNAZ 42.02
- Support Level
- INBS $0.92
- RNAZ $10.90
- Resistance Level
- INBS $1.06
- RNAZ $13.92
- Average True Range (ATR)
- INBS 0.06
- RNAZ 1.04
- MACD
- INBS 0.01
- RNAZ -0.44
- Stochastic Oscillator
- INBS 42.86
- RNAZ 8.60
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.